![Marc Augustin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 121 264 $ al 31/05/2026
Marc Augustin currently works at PolyPeptide Group AG, as Chief Financial Officer from 2024.
Mr. Augustin also formerly worked at Lonza AG, as Vice President-Finance and Smith & Nephew Schweiz AG, as Head-Finance from 2009 to 2016.
Mr. Augustin received his undergraduate degree from Heinrich-Heine-Universität Düsseldorf.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
POLYPEPTIDE GROUP AG 0,01 % | 31/12/2025 | 2.500 ( 0,01 % ) | 121 264 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| POLYPEPTIDE GROUP AG | Director Financiero/CFO | 02/01/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Smith & Nephew Schweiz AG | Corporate Officer/Principal | 01/01/2016 |
Lonza AG
 Lonza AG BiotechnologyHealth Technology Engages in developing, producing and selling pharmaceutical and chemical products | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 4 |
|---|---|
Heinrich-Heine-Universität Düsseldorf
 Heinrich-Heine-Universität Düsseldorf Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lonza AG
Lonza AG BiotechnologyHealth Technology Engages in developing, producing and selling pharmaceutical and chemical products | Health Technology |
Smith & Nephew Schweiz AG | |
PolyPeptide Group AG
 PolyPeptide Group AG BiotechnologyHealth Technology Manufactures polypeptide and custom peptide synthesis | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
